Company Overview
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Recent Developments
- Dec 2025 Revenue of $800.00K (-77.1% YoY); net profit $-45.35M.
- Trailing 12 Months Year-on-year growth — revenue -77.1%.
- 5-Year Trend Long-term compounding — revenue CAGR -38.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -38.64% |
| 1 Year: | -77.14% |
Stock Price Performance
| 1 Year: | -64.44% |
| 6 Months: | -14.70% |
| 3 Months: | -10.30% |
| 1 Month: | -11.25% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.40 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -38.6% CAGR over 5 years.
- Trading 65.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IMA ImageneBio, Inc. PHARMA | 5.05 | -1.07 | $57.32M | 0.00% | -34.18% | -82.68% | -38.64% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.23M | 3.07M | 2.83M | 3.47M | 3.55M | 3.75M | 3.38M | 382.00K | 6.40M | 5.31M | 2.00M | 1.19M | - | - | 3.50M | 800.00K | - | - | - | - |
| Operating Income | -7.18M | -5.06M | -6.23M | -9.72M | -12.69M | -14.52M | -16.96M | -20.95M | -17.88M | -15.52M | -18.49M | -19.50M | -18.23M | -15.82M | -2.04M | -6.00M | -8.75M | -26.59M | -12.08M | -11.78M |
| Net Income | -6.95M | -5.04M | -6.22M | -9.72M | -12.68M | -14.52M | -16.84M | -20.49M | -17.34M | -14.22M | -17.11M | -17.34M | -22.31M | -6.26M | -3.18M | -6.08M | -7.58M | -24.78M | -10.62M | -10.18M |
| Diluted EPS | - | - | - | - | -0.35 | -0.40 | -0.47 | -0.57 | -0.48 | -0.39 | -0.44 | -0.40 | -0.33 | -0.28 | -2.58 | -3.80 | -0.06 | -2.91 | -0.95 | -0.63 |
| R&D Expense | 7.89M | 6.33M | 7.22M | 10.02M | 11.37M | 13.38M | 14.34M | 15.49M | 18.85M | 15.55M | 15.17M | 14.65M | 9.64M | 9.83M | 3.88M | 4.04M | 4.03M | 15.56M | 5.96M | 6.67M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 9.19M | 30.98M | 15.62M | 9.16M | 3.50M | 800.00K |
| Operating Income | -44.52M | -34.14M | -70.90M | -75.42M | -37.00M | -48.45M |
| Net Income | -44.26M | -34.12M | -68.77M | -68.17M | -36.57M | -45.35M |
| Diluted EPS | - | -1.22 | -1.90 | -1.63 | -22.10 | -9.64 |
| R&D Expense | 44.85M | 47.11M | 64.32M | 59.65M | 32.11M | 28.52M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 168.40M | 247.88M | 172.26M | 192.09M | 15.92M | 152.98M |
| Total Equity | -61.46M | -101.05M | 207.88M | 146.97M | -126.11M | -160.56M | 133.14M |
| Cash & Equivalents | - | 162.49M | 232.22M | 59.92M | 119.89M | 12.12M | 94.53M |
| Total Liabilities | - | 63.47M | 40.00M | 25.29M | 22.34M | 17.45M | 19.84M |
| Current Liabilities | - | 28.33M | 27.19M | 21.50M | 14.21M | 17.21M | 11.23M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -37.83M | -60.25M | -74.11M | -79.74M | -21.32M | -47.84M |
| Investing Cash Flow | 2.92M | -1.76M | -99.28M | 64.14M | 11.12M | -5.81M |
| Financing Cash Flow | 116.18M | 131.74M | 1.09M | 75.98M | 6.91M | 135.47M |
| Capital Expenditure | -766.00K | -1.76M | -1.43M | -414.00K | - | - |
| Free Cash Flow | -38.59M | -62.01M | -75.54M | -80.16M | - | - |
| Share Buybacks | - | - | - | 663.00K | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -484.2% | -110.2% | -454.0% | -823.3% | -1,057.1% | -6,056.4% |
| Net Margin % | -481.4% | -110.1% | -440.3% | -744.2% | -1,044.8% | -5,668.6% |
| ROE % | 43.8% | -16.4% | -46.8% | 54.1% | 22.8% | -34.1% |
| ROCE % | -31.8% | -15.5% | -47.0% | -42.4% | 2,874.9% | -34.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | BVF Inc. | 9.78% | 1.11M | $5.43M |
| 2 | Blue Owl Capital Holdings LP | 8.08% | 917.69K | $4.49M |
| 3 | Orbimed Advisors LLC. | 8.01% | 909.27K | $4.45M |
| 4 | Cable Car Capital, LP | 6.89% | 781.60K | $3.82M |
| 5 | Omega Fund Management, Llc | 4.01% | 455.36K | $2.23M |
| 6 | RTW Investments LP | 2.95% | 334.44K | $1.64M |
| 7 | Vanguard Capital Management LLC | 2.82% | 320.52K | $1.57M |
| 8 | Trails Edge Capital Partners, LP | 2.48% | 282.00K | $1.38M |
| 9 | BML Capital Management, LLC | 1.77% | 200.73K | $981.57K |
| 10 | Monashee Investment Management LLC | 1.69% | 192.34K | $940.56K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMA
A biotech CEO will speak in New York. ImageneBio will archive the webcast for 90 days. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPV3J4cUhJZnJKSkRHWW9pSWtmb3lCU1ROejFVbE0zVWlBSGQ2WEhNbVh5cGtfQ2JucUp3dTNJWkQxVExXb19BNkQtOXh6Ql9lT0ljUHNrOWczQlIwSHFRdF9CUGFVYjhRWE44TS1mSU4zZUV0YWY5akhMcmpNZDRiOWNNUjBUaWxWSFd5Tj…
Image Resources NL (ASX:IMA) On The Verge Of Breaking Even - simplywall.st
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPSUZoQS15ZWxETk8zQklVTC1aVmtXWGlZTXFQUXBxYmZIREw4ZFhpTnc5dlFuMlZjcWd2eTdsNnYwMUpVYV9CdWRpci1keEtEMzFfLUdna1pSZnJNYTJfUXh0Nm5XUTRmQ0RFckxOTXZYUFFCMTdiTnAwZ1l0b1ptTHF3SGxVNk1hTDBfcU…
ImageneBio, Inc. (NASDAQ: IMA) Share Price, IMA Stock News, IMA Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVEFVX3lxTFAtbDdwVWFxcUxqNXBfa1J4ZUFGSl9CZXRlTEwxTS1ERGlENGRyaVExQUlZekhVRXgtTFNhNlR4b1RfWTctZ09vYXYwako4QUgwMDhvSg?oc=5" target="_blank">ImageneBio, Inc. (NASDAQ: IMA) Share Price, IMA Stock…
IMA - Finviz
<a href="https://news.google.com/rss/articles/CBMiREFVX3lxTFByS08tUWZrWU54UzhCYl8xUjZKWG01LXhJWFYzUXV1enY0MG5MRmxxU0dVOWZPRExGc2FkODhpZWVBX013?oc=5" target="_blank">IMA</a> <font color="#6f6f6f">Finviz</font>…
IMA Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE9KM3pVdVM0MWdyNHFLUUd6NjItTm1zeXdrMHJlTHR5MjR2azk1SkkwYkZFdFFHcmxqR0V0U3VTd3hwekI0NHNLQllEem0wLTlxak1GMUplbm1oUlNVaGxaNEdSaG5ydDFQdE4xQjNUbUpQWW91Q1ZWZw?oc=5" target="_blank">IMA F…
American Tungsten ($TUNG) Accelerates Toward Production At The IMA Mine In Idaho Davis Schneider (xahAqyuKLL) - Mshale
<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE9wX2VTNE5lN0ZON3RxMFZWRmJOVVpmYjVVNzV1d0NyMVQ1dEFicjIza0RncmxjTjkwODJQMHlMdkpobTVGRlUzVVdveXJjZ2RTc0E3YlhUMjRrMUU?oc=5" target="_blank">American Tungsten ($TUNG) Accelerates Toward…
IMA — Frequently Asked Questions
What is the current share price of ImageneBio, Inc. (IMA)?
As of 2026-09-19 21:16 PDT, ImageneBio, Inc. (IMA) trades at $5.05 on NasdaqCM. Its 52-week range is $4.55 to $14.79.
What is the market capitalisation of IMA?
ImageneBio, Inc. (IMA) has a market capitalisation of $57.32M on NasdaqCM.
What is the P/E ratio of IMA?
IMA trades at a trailing price-to-earnings (P/E) ratio of -1.07. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.39.
What is the return on equity (ROE) of IMA?
IMA has a return on equity (ROE) of -82.68%. Its return on capital employed (ROCE) is -34.18%.
Is IMA a good stock to buy?
This page provides a data-driven analysis of ImageneBio, Inc. (IMA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.